



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448-B-20

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

**Complete if Known**

Application Number	10/814,109
Filing Date	03/30/2004
First Named Inventor	Michael W. Salter
Art Unit	1614
Examiner Name	
Attorney Docket Number	2560.004

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)			
JS		EP 1 244 638 B1	05/12/2004	University of Bristol and	
				University of Nebraska	
				Board of Regents	

**Examiner  
Signature**

Date  
Considered

X/30/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

2

**Complete if Known**

Application Number

10/814,109

Filing Date

03/30/2004

First Named Inventor

Michael W. Salter

Art Unit

1614


Examiner Name

Attorney Docket Number

2560.004

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SS		M. INGMAN et al, "NADH dehydrogenase subunit 2 [Homo sapiens]", Genbank, Accession No. AAK17260 (August 22, 2003)	
SS		S. LEI et al, "Platelet-derived growth factor receptor-induced feed-forward inhibition of excitatory transmission between hippocampal pyramidal neurons", J. Biol. Chem., 274(43):30617-30623 (October, 1999)	
SS		M. CHEN et al, "Tyrosine kinase and tyrosine phosphatase participate in regulation of interactions of NMDA receptor subunit 2A with Src and Fyn mediated by PSD-95 after transient brain ischemia", Neuroscience Letters, 339:29-32 (March, 2003)	

Examiner  
SignatureDate  
Considered

8/30/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Application Number	
		Filing Date	
		First Named Inventor	Michael W. Salter
		Art Unit	
		Examiner Name	
Sheet 1 of 8	Attorney Docket Number	2560.004	

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
SS		US- 4,994,446	02/19/1991	M. Sokolovsky	
JS		US- 5,888,996	03/30/1999	D. Farb	
SS		US- 5,914,403	06/22/1999	A. Nichols	
JS		US- 6,653,354	11/25/2003	N. Franks	
JS		US- 6,703,489	03/09/2004	D. Ish-Horowicz	
SS		US- 2002/0077322 A1	06/20/2002	G. Ayoub	
JS		US- 2002/0123510 A1	09/05/2002	B. Chenard	
JS		US- 2003/0050243 A1	03/13/2003	M. Tymianski	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
		</				

Examiner Signature		Date Considered	8/30/06
-----------------------	---	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number			
		Filing Date			
		First Named Inventor	Michael W. Salter		
		Art Unit			
		Examiner Name			
Sheet	2	of	8	Attorney Docket Number	2560.004

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SS		M. AARTS et al, "Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions", Science, 298:846-850 (October, 2002)	
SS		W-Y. LU et al, "G-protein-coupled receptors act via protein kinase C and Src to regulate NMDA receptors", Nature Neuroscience, 2(4):331-338 (April, 1999)	
SS		X-M. YU et al, "Gain control of NMDA-receptor currents by intracellular sodium", Nature, 396:469-473 (December, 1998)	
SS		K. PELKEY et al, "Tyrosine phosphatase STEP is a tonic brake on induction of long-term potentiation", Neuron, 34:127-138 (March, 2002)	
SS		Y-Q. HUANG et al, "CAKB/Pyk2 kinase is a signaling link for induction of long-term potentiation in CA1 hippocampus", Neuron, 29:485-496 (February, 2001)	
SS		Y. LU et al, "Src activation in the induction of long-term potentiation in CA1 hippocampal neurons", Science, 279:1363-1367 (February, 1998)	
SS		X-M. YU et al, "NMDA channel regulation by channel-associated protein tyrosine kinase Src", Science, 275:674-677 (January, 1997)	
SS		G. SHEPHERD et al, "Three-dimensional structure and composition of CA3-CA1 axons in rat hippocampal slices: implications for presynaptic connectivity and compartmentalization", The Journal of Neuroscience, 18(20):8300-8310 (October, 1998)	
SS		J. WALKER, "The NADH:ubiquinone oxidoreductase (complex I) of respiratory chains", Quarterly Reviews of Biophysics, 25(3):253-324 (1992)	
SS		D. ALI et al, "NMDA receptor regulation by Src kinase signaling in excitatory synaptic transmission and plasticity", Current Opinion in Neurobiology, 11:336-342 (2001)	

Examiner Signature		Date Considered	9/30/02
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	
		Filing Date	
		First Named Inventor	Michael W. Salter
		Art Unit	
		Examiner Name	
Sheet	3	of	8
		Attorney Docket Number	2560.004

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SS		M. BROWN et al, "Regulation, substrates and functions of src", Biochimica et Biophysica Acta, 1287:121-149 (1996)	
JS		J. COYLE et al, "Oxidative stress, glutamate, and neurodegenerative disorders", Science, 262:689-695 (October, 1993)	
SS		S. DAVIS et al, "Selfotel in acute ischemic stroke possible neurotoxic effects of an NMDA antagonist", Stroke, 31:347-354 (February, 2000)	
SS		V. DAWSON et al, "Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures", Proc. Natl. Acad. Sci. USA, 88:6368-6371 (July, 1991)	
JS		R. DINGLELINE et al, "The glutamate receptor ion channels", Pharmacological Reviews, 51(1):7-61 (1999)	
SS		I. FEARNLEY et al, "Conservation of sequences of subunits of mitochondrial complex I and their relationships with other proteins", Biochimica et Biophysica Acta, 1140:105-134 (1992)	
SS		A. FIX et al, "Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)-801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex", Experimental Neurology, 123:204-215 (1993)	
SS		D. FRIEL et al, "Mitochondria as regulators of stimulus-evoked calcium signals in neurons", Cell Calcium, 28(5/6):307-316 (2000)	
SS		J. HENDERSON et al, "The receptor tyrosine kinase EphB2 regulates NMDA-dependent synaptic function", Neuron, 32:1041-1056 (December, 2001)	
SS		N. IBRAHIM et al, "Regulation of mitochondrial protein synthesis at the polyribosomal level", The Journal of Biological Chemistry, 251(1):108-115 (January, 1976)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	
		Filing Date	
		First Named Inventor	Michael W. Salter
		Art Unit	
		Examiner Name	
Sheet	4	of	8
		Attorney Docket Number	2560.004

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SS		E. KRAMAR et al, "Integrins modulate fast excitatory transmission at hippocampal synapses", The Journal of Biological Chemistry, 278(12):10722-10730 (March, 2003)	
SS		B. LIN et al, "Integrins regulate NMDA receptor-mediated synaptic currents", J. Neurophysiol., 89:2874-2878 (May, 2003)	
SS		J. MACDONALD et al, "Regulation of N-methyl-D-aspartate receptors revealed by intracellular dialysis of murine neurones in culture", Journal of Physiology, 414:17-34 (1989)	
SS		N. SANS et al, "A developmental change in NMDA receptor-associated proteins at hippocampal synapses", Journal of Neuroscience, 20(3):1260-1271 (February, 2000)	
SS		B. SOLTYS et al, Trends in Biochemical Science, 24:174-177 (1999)	
SS		M. TAKASU et al, "Modulation of NMDA receptor-dependent calcium influx and gene expression through EphB receptors", Science, 295:491-495 (January, 2002)	
SS		K. WU et al, "The synthesis of ATP by glycolytic enzymes in the postsynaptic density and the effect of endogenously generated nitric oxide", Proc. Natl. Acad. Sci. USA, 94:13273-13278 (November, 1997)	
SS		Y. WANG et al, "Regulation of NMDA receptors by tyrosine kinases and phosphatases", Nature, 369:233-235 (May, 1994)	
SS		B. SOLTYS et al, "Mitochondrial proteins at unexpected cellular locations: export of proteins from mitochondria from an evolutionary perspective", International Review of Cytology, 194:133-196 (1999)	
SS		C. IKONOMIDOU et al, "Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?", The Lancet Neurology, 1:383-386 (October, 2002)	

Examiner Signature		Date Considered	8/30/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number			
		Filing Date			
		First Named Inventor	Michael W. Salter		
		Art Unit			
		Examiner Name			
Sheet	5	of	8	Attorney Docket Number	2560.004

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CS		E. KANDEL, "The molecular biology of memory storage: a dialogue between genes and synapses", Science, 294:1030-1038 (November, 2001)	
SS		M. KENNEDY et al, "Biochemical and immunochemical evidence that the 'major postsynaptic density protein' is a subunit of a calmodulin-dependent protein kinase", Proc. Natl. Acad. Sci. USA, 80(23):7357-7361 (December, 1983)	
KS		X. LIU et al, "Potentiation of formalin-evoked adenosine release by an adenosine kinase inhibitor and an adenosine deaminase inhibitor in the rat hind paw: a microdialysis study", European Journal of Pharmacology, 408:143-152 (2000)	
CS		L. LUTTRELL et al, "The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals", Journal of Cell Science, 115:455-465 (2002)	
SS		R. MALENKA et al, "Long-term potentiation - a decade of progress?", Science, 285:1870-1874 (September, 1999)	
SS		P. MARIOTTINI et al, "Identification of the polypeptides encoded in the unassigned reading frames 2, 4, 4L, and 5 of human mitochondrial DNA", Proc. Natl. Acad. Sci. USA, 83:1563-1567 (March, 1986)	
CS		M. MARUSICH et al, "Expression of mtDNA and nDNA encoded respiratory chain proteins in chemically and genetically-derived Rho0 human fibroblasts: a comparison of subunit proteins in normal fibroblasts treated with ethidium bromide and fibroblasts from a patient with mtDNA depletion syndrome", Biochimica et Biophysica Acta, 1362:145-159 (1997)	
CS		G. MORRIS et al, "Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two Phase III clinical trials", J. Neurosurg., 91:737-743 (1999)	
CS		M. MATTSON, "Apoptosis in neurodegenerative disorders", Nature Reviews - Molecular Cell Biology, 1:120-129 (October, 2000)	
CS		K. MURAI et al, "Can Eph receptors stimulate the mind?", Neuron, 33:159-162 (January, 2002)	

Examiner Signature		Date Considered	8/30/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number			
		Filing Date			
		First Named Inventor	Michael W. Salter		
		Art Unit			
		Examiner Name			
Sheet	6	of	8	Attorney Docket Number	2560.004

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SS		L. PEI et al, "Transient cerebral ischemia increases tyrosine phosphorylation of the synaptic RAS-GTPase activating protein, SynGAP", Journal of Cerebral Blood Flow and Metabolism, 21:955-963 (2001)	
SS		R. PETRALIA et al, "Selective acquisition of AMPA receptors over postnatal development suggests a molecular basis for silent synapses", Nature Neuroscience, 2(1):31-36 (January, 1999)	
SS		R. PLANELLAS-CASES et al, "Small molecules targeting the NMDA receptor complex as drugs for neuropathic pain", Mini Reviews in Medicinal Chemistry, 3:749-756 (2003)	
SS		A. RAMACHANDRAN et al, "Inhibition of mitochondrial protein synthesis results in increased endothelial cell susceptibility to nitric oxide-induced apoptosis", Proc. Natl. Acad. Sci. USA, 99(10):6643-6648 (May, 2002)	
SS		M. REERS et al, "J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential", Biochemistry, 30:4480-4486 (1991)	
SS		R. RIZZUTO, "Intracellular Ca <sup>2+</sup> pools in neuronal signaling", Current Opinion in Neurobiology, 11:306-311 (2001)	
SS		P. SANNA et al, "A role for Src kinase in spontaneous epileptiform activity in the CA3 region of the hippocampus", Proc. Natl. Acad. Sci. USA, 97(15):8653-8657 (July, 2000)	
SS		L. SAZANOV et al, "Cryo-electron crystallography of two sub-complexes of bovine complex I reveals the relationship between the membrane and peripheral arms", J. Mol. Biol., 302:455-464 (2000)	
SS		L. SAZANOV et al, "Resolution of the membrane domain of bovine complex I into subcomplexes: implications for the structural organization of the enzyme", Biochemistry, 39:7229-7235 (2000)	
SS		R. SCANNEVIN et al, "Postsynaptic organization and regulation of excitatory synapses", Nature Reviews Neuroscience, 1:133-141 (November, 2000)	

Examiner Signature		Date Considered	7/30/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number			
		Filing Date			
		First Named Inventor	Michael W. Salter		
		Art Unit			
		Examiner Name			
Sheet	7	of	8	Attorney Docket Number	2560.004

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
Q		M. SHENG et al, "Postsynaptic signaling and plasticity mechanisms", Science, 298:776-780 (October, 2002)	
SS		M. SHENG et al, "Ligand-gated ion channel interactions with cytoskeletal and signaling proteins", Annu. Rev. Physiol., 62:755-778 (2000)	
SS		P. SIEKEVITZ, "The postsynaptic density: a possible role in long-lasting effects in the central nervous system", Proc. Natl. Acad. Sci. USA, 82:3494-3498 (May, 1985)	
SS		R. SIMON et al, "Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain", Science, 226:850-852 (November, 1984)	
SS		R. WALIKONIS et al, "Identification of proteins in the postsynaptic density fraction by mass spectrometry", Journal of Neuroscience, 20(11):4069-4080 (June, 2000)	
S		S. HIRSCH et al, "A pivotal role for glutamate in the pathogenesis of schizophrenia, and its cognitive dysfunction", Pharmacology Biochemistry and Behavior, 56(4):797-802 (1997)	
SS		W. GUO et al, "Tyrosine phosphorylation of the NR2B subunit of the NMDA receptor in the spinal cord during the development and maintenance of inflammatory hyperalgesia", The Journal of Neuroscience, 22(14):6208-6217 (July, 2002)	
SS		A. GORMAN et al, "Role of Mitochondria in Neuronal Apoptosis", Developmental Neuroscience, 22:348-358 (2000)	
SS		T. SMART, "Regulation of excitatory and inhibitory neurotransmitter-gated ion channels by protein phosphorylation", Current Opinion in Neurobiology, 7:358-367 (1997)	
Q		T. PAWSON, "Protein modules and signaling networks", Nature, 373:573-580 (February, 1995)	

Examiner Signature		Date Considered	8/30/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	
		Filing Date	
		First Named Inventor	Michael W. Sálter
		Art Unit	
		Examiner Name	
Sheet	8	of	8
		Attorney Docket Number	2560.004

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SW		J. GYURIS et al, "Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2", Cell, 75:791-803 (November, 1993)	
SW		X. LIU et al, "Regulation of c-Src tyrosine kinase activity by the Src SH2 Domain", Oncogene, 8:1119-1126 (1993)	

Examiner Signature		Date Considered	2/30/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.